← Leaderboards
Yong Qin
University Of Texas El Paso
$992,246
Attributed
$992,246
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $531.7K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$992,246 · 2
By mechanism
R16$614,000 · 1
U54$378,246 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Pre-Clinical”
- Nancy Jean Sullivan · Boston University Medical Campus$34,500,000
- Taleen Hanania · Psychogenics, Inc.$21,254,211
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Chris Maxwell · National Institute Of Allergy And Infectious Diseases$12,000,000
Research focus
Pre-ClinicalMelanomaImmune ResponsePatient ResponseTumor ImmunityNew Therapeutic TargetImmuneImmune ResistanceMalignant NeoplasmsNovel Therapeutic InterventionTumorTumor-Immune System InteractionsTumor MicroenvironmentResponseCancer TypeCytotoxic T-LymphocytesCytokine SignalingImmune Checkpoint InhibitorImmunotherapyMalignant Breast NeoplasmEffectivenessDrug TargetingEffective TherapyCancer Center
Grant awards (5)
Targeting the immunosuppressive adenosine-axis to overcome T-cell γc cytokine signaling blockade and enhance antitumor immunity in hepatocellular carcinoma$378,246
U54 · FY2025 · MD · contact PI
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy$153,500
R16 · FY2025 · GM · contact PI
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy$153,500
R16 · FY2024 · GM · contact PI
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy$153,500
R16 · FY2023 · GM · contact PI
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy$153,500
R16 · FY2022 · GM · contact PI